A Phase 2, Open-label Study to Evaluate the Safety and Efficacy of MK7684A (MK-7684 [Vibostolimab] with MK-3475 [Pembrolizumab] Coformulation) in Participants with Relapsed or Refractory Hematological Malignancies Monika Chaudhry | January 30, 2022
